Recent Posts

• PEPTILOGICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B STUDY OF PLG0206 FOR PERIPROSTHETIC JOINT INFECTION
• Disrupters: Jonathan Steckbeck
• PEPTILOGICS RECEIVES FDA FAST TRACK DESIGNATION FOR PLG0206, AN INVESTIGATIONAL PEPTIDE THERAPEUTIC IN DEVELOPMENT FOR THE TREATMENT OF PERIPROSTHETIC JOINT INFECTION
• Peptilogics proposed treatment for joint infection moves forward
• In Her Own Words: Covid propels Teresa Whalen to improve cancer treatment